VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LKFT
  4. Financial Ratios

Lakefront Biotherapeutics N.V. (LKFT) Financial Ratios

Latest Ratios: P/E Ratio 2.6x · EV/EBITDA 4.0x · ROE 9.9%. (2004–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LKFT Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.3B$2.2B$1.8B$2.7B$2.9B$3.6B$6.4B$11.9B$4.8B$4.6B$2.9B
Enterprise Value$2.2B$2.1B——$2.4B$1.4B$4.3B$10.1B$3.5B$3.5B$2.0B
P/E Ratio →2.586.7124.5512.66———79.55——56.31
P/S Ratio2.211.946.6011.1712.097.4513.4714.2716.5536.5022.65
P/B Ratio0.640.67——1.151.372.414.143.944.583.87
P/FCF———————3.34——12.50
P/OCF———————3.31——12.25

P/E links to full P/E history page with 30-year chart

LKFT EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.86——10.072.909.0712.0712.0827.4515.13
EV / EBITDA3.983.72—————26.93———
EV / EBIT3.926.84—————27.34———
EV / FCF———————2.82——8.35

LKFT Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin97.3%97.3%87.4%100.0%100.0%99.7%-9.5%49.7%-11.8%-71.9%-7.8%
Operating Margin45.1%45.1%-68.3%-36.8%-54.3%-34.2%-37.4%44.2%-15.5%-70.7%-8.9%
Net Profit Margin28.8%28.8%26.9%88.3%-90.4%-25.9%-63.9%17.9%-10.1%-91.0%41.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE9.9%9.9%——-8.4%-4.7%-11.0%7.3%-2.6%-13.1%9.6%
ROA9.4%9.4%——-4.4%-2.3%-5.2%4.0%-2.1%-9.8%7.1%
ROIC11.8%11.8%——-7.9%-24.8%-16.7%57.4%———
ROCE15.4%15.4%——-3.0%-3.4%-3.4%11.0%-3.8%-8.6%-1.7%

LKFT Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.000.00——0.010.010.010.01—0.000.00
Debt / EBITDA0.010.01—————0.07———
Net Debt / Equity—-0.03——-0.19-0.83-0.79-0.64-1.06-1.14-1.28
Net Debt / EBITDA-0.15-0.15—————-4.91———
Debt / FCF———————-0.51——-4.15
Interest Coverage136.71136.71-2.394.18-6.74-10.54-15.42199.92-39.28-122.40-244.47

Net cash position: cash ($88M) exceeds total debt ($7M)

LKFT Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio20.1520.15——8.118.588.4510.266.046.989.70
Quick Ratio20.0020.00——8.018.558.4510.266.046.979.70
Cash Ratio19.6119.61——7.838.308.1210.115.876.709.38
Asset Turnover—0.33——0.050.090.080.140.200.100.12
Inventory Turnover1.321.32——0.590.081475.121647.411169.84783.16465.25
Days Sales Outstanding—17.46——117.0296.81132.3935.0242.38120.0266.16

LKFT Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield38.8%14.9%4.1%7.9%———1.3%——1.8%
FCF Yield———————30.0%——8.0%
Buyback Yield0.0%0.0%——0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$66M$66M$66M$66M$66M$65M$58M$52M$49M$46M

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Unsustainable profit-driven deleveraging

Low Multiples Reflect One-Time Earnings

Based on reported figures, LKFT trades at a P/E of 2.58 and EV/EBITDA of 3.98, multiples that appear depressed against Incyte's 60.00 P/E and 26.65 EV/EBITDA and may be inflated in their apparent cheapness by a single quarter's earnings.

The 2.58 trailing P/E is computed on earnings dominated by the $782.1M net income in 2025Q4, a figure that appears non-recurring given operating losses in adjacent quarters. Against a P/B of 0.64, the market appears to be pricing the equity near its book value, which suggests skepticism toward the durability of reported earnings rather than a clear value signal. Investors should monitor whether trailing multiples remain low once the 2025Q4 gain is excluded, since the current figures warrant further investigation before being treated as evidence of undervaluation.

Margins Swing on Lumpy Revenue

Gross margin in LKFT's reported figures ranged from -185.8% in 2026Q2 to 99.9% in 2025Q4, while operating margin reached -87.3% in 2025Q2, indicating earnings power that does not behave like a stable operating business.

The dispersion in gross margin suggests cost of revenue does not scale with the revenue line, so a single quarter's margin tells little about structural economics. Operating margin of -5.4% in 2026Q3 against R&D burden implies research spending continues to outrun the revenue base, based on reported figures. Net margin appears to be driven by non-operating items, as the 86.8% figure in 2025Q4 diverges sharply from operating results, so operating margin is the more reliable gauge of earning power here.

Returns Spike Without Compounding Base

As reported in the filings, ROIC was -1.0% in 2026Q3 and -1.5% in 2026Q1, with a single 20.5% reading in 2025Q4 that appears to reflect the one-time gain rather than durable capital productivity.

The 2025Q4 ROIC and ROE spike of 20.5% and 27.5% sits against negative ROIC in every other reported quarter with data, so it does not indicate a compounding trend. Returns are better described as episodic than as evidence of a durable capital base. Investors should monitor whether returns remain positive once the non-recurring gain is removed from the calculation.

Current Ratio Masks Thin Cash Cushion

Based on LKFT's reported figures, the current ratio of 46.49 in 2026Q3 looks exceptionally strong, yet cash of $96.3M against quarterly operating outflows of roughly $33M to $83M implies a short runway relative to burn.

A current ratio this elevated is less informative than the absolute cash balance, which appears thin against recurring operating cash losses. Quick ratio of 46.39 is nearly identical, suggesting current assets are dominated by cash and receivables rather than inventory, which means liquidity depends heavily on continued access to the existing balance. Under severe stress, the position may not hold if operating outflows persist at recent levels, though this warrants further investigation given limited disclosure.

Misapplied Ratio: Current Ratio

The current ratio is most commonly misapplied to a pre-revenue biotech like LKFT, where it can show extreme comfort while cash burn quietly erodes the runway that the ratio fails to capture.

A current ratio of 46.49 appears to signal strength, but it obscures that liquidity is measured against a balance sheet whose current assets may not convert to cash fast enough to fund quarterly operating outflows. Free cash flow runway, measured as cash divided by average quarterly burn, is a more relevant metric for assessing survival time. Investors should monitor that figure, since the present ratio does not reveal how quickly the cash base is being consumed.

Download Financial Ratios Data

Includes 30+ ratios · 22 years · Updated daily

Consensus & Technical Research Suite
Open LKFT Terminal

LKFT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

What is Lakefront Biotherapeutics N.V.'s P/E ratio?

Lakefront Biotherapeutics N.V.'s current P/E ratio is 2.6x. The historical average is 32.8x.

What is Lakefront Biotherapeutics N.V.'s EV/EBITDA?

Lakefront Biotherapeutics N.V.'s current EV/EBITDA is 4.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 15.3x.

What is Lakefront Biotherapeutics N.V.'s ROE?

Lakefront Biotherapeutics N.V.'s return on equity (ROE) is 9.9%. The historical average is -8.4%.

Is LKFT stock overvalued?

Based on historical data, Lakefront Biotherapeutics N.V. is trading at a P/E of 2.6x. Compare with industry peers and growth rates for a complete picture.

What are Lakefront Biotherapeutics N.V.'s profit margins?

Lakefront Biotherapeutics N.V. has 97.3% gross margin and 45.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.

How much debt does Lakefront Biotherapeutics N.V. have?

Lakefront Biotherapeutics N.V.'s Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.